[A24-107] Delgocitinib (moderate to severe chronic hand eczema) – Benefit assessment according to §35a Social Code Book V
Last updated 03.04.2025
Project no.:
A24-107
Commission:
Commission awarded on 15.10.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Skin and hair
Adult patients with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-107
| Project no. | Title | Status |
|---|---|---|
| A25-37 | Delgocitinib (moderate to severe chronic hand eczema) – Addendum to Project A24-107 | Commission completed |
Federal Joint Committee (G-BA)
03-04-2025 A G-BA decision was published.
G-BA documents on this decision